RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Roivant Sciences, Vivek Ramaaswamy’s umbrella biotech company, agreed to a memorandum of understanding to sell ownership to five of its Vant companies to Japan’s Sumitomo Dainippon Pharma. The upfront stakes are $3 billion. In addition, Sumitomo Dainippon is acquiring an equity stake of more than 10% of Roivant shares. The Japanese pharma company will also have options to buy up to six additional Vants and gain access to Roivant’s proprietary technology platforms, DrugOme and Digital Innovation.
